RxAdherence 2013 Draft Agenda
Published: January 28th, 2013
Organized by the Healthcare Compliance Packaging Council, the day-long conference set for March 12 seeks to tackle patient noncompliance. HCPC (www.hcpconline.org) shares the agenda:
• Opening Keynote presentation: “Efforts to Advance Medication Adherence, Savings, and Outcomes In a Deficit Reduction Environment,” by Joel White, Health Coverage Executive Director, Council for Affordable Healthcare
Poor medication adherence, or non-adherence, affects patient health by reducing the ability to effectively manage and control chronic diseases. Patients with adherence issues are more likely to experience preventable disease progression, increased hospitalizations, and doctor and emergency room visits. As a result of Congress and the Administration’s efforts to lower health spending, there may be opportunities to advance medication adherence in Medicare, Medicaid, and private markets. White will explore efforts to advance medication adherence policy as Congress considers the next round of deficit reduction measures.
• “Estimated Annual Pharmaceutical Revenue Loss Due to Medication Non-Adherence,” by Thomas Forissier, Principal, Capgemini Consulting’s Life Sciences Sector and co-lead of the Life Sciences Customer Experience Practice, Capgemini Consulting & Katrina Firlik, MD, Chief Medical Officer, HealthPrize Technologies
The New England Healthcare Institute estimated that medication non-adherence is responsible for $290 billion in “otherwise avoidable medical spending” in the United States alone each year. On the pharmaceutical revenue side, however, the impact of medication non-adherence had yet to be accurately quantified. The market assumption relied upon to date, and quoted extensively, has been $30 billion globally, which we felt was a gross underestimate. This presentation will cover the most accurate estimate of pharmaceutical revenue loss due to medication non-adherence and how increasing adherence rates by only 10 percentage points would translate into a $41 billion pharmaceutical revenue opportunity in the US ($124 billion globally), accompanied by improved health outcomes and decreased healthcare spending.
• “Improving Medication Adherence and Reducing Readmissions,” by Thomas E. Hubbard, Vice President for Policy Research, NEHI
New government payment reforms are penalizing hospitals for readmissions, and innovative providers are responding with better planning and follow-up care. Medication management is at the heart of this effort. This presentation will review these models of discharge planning and follow-up care that not only reduce readmissions but highlight the valuable role of medication management the need for improved medication adherence.
• “The A3 Project: Developing a Collaborative Adherence Action Agenda,” by Ray Bullman, Executive Vice President, National Council on Patient Information and Education
Representatives from over two dozen diverse organizations have come together to provide input into the development of a comprehensive, collaborative, multi-stakeholder Adherence Action Agenda (The A3 project), addressing four key focus areas: Chronic Conditions and Co-Morbidities; Critical Macro Factors; Patient-related Factors, and Healthcare Professional Factors. This session will provide an update on the formulation of the strategic project framework, implementation schedule, identification of lead monitoring organizations, and next steps. Support for the initial phase of the multi-year A3 Project provided by Merck.
• HCPC Compliance Package of the Year Awards Ceremony & Presentation of Winning Packages
• “Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence,” Michael Eaddy, PharmD, PhD, Vice President, Xcenda and Justin Schroeder, Senior Director, Marketing & Development Services, AndersonBrecon
The use of unit-dose calendarized formats is one tool in addressing the underlying causes of poor adherence. In this presentation, Michael Eaddy and Justin Anderson will present the findings of the recently published Xcenda study conducted to highlight successful patient adherence improvements using the Novartis Pharmaceuticals’ DiovanHCT antihypertensive therapy in a 30-day reminder package distributed by a major retail pharmacy.
• “Improving Patient Adherence in Clinical Trials,” by Kathy Zonca, Patient Adherence Consultant, C3i Inc.
Patient adherence has been described as the “other” drug problem in routine clinical practice. But is it an issue in clinical trials where one expects the patients to be more highly motivated to adhere? In this session, we will explore reasons that adherence might be lower than desired in trials and how non-adherence can impact clinical research results. We will also look at other closely related areas of concern that can impact the integrity of trial data. Finally, we will offer some suggestions for ways to improve patient adherence in the clinical trial setting.
• “Delivering Breakthrough Medicine with Device Innovation,” Mark Novara, Worldwide Strategic Marketing Director, BD Medical-Pharmaceutical Systems
This talk will cover three main objectives: key design principles to device innovation; best practices to execute these design principles; and case study on the BD Microinfusor patch injector (novel, high volume delivery solution).
• “Industry Perspective Panel” Join industry experts as they collaborate on the effective methods of improving patient adherence based on their knowledge and experience in the field.